Yoshida et al. [171] found that CUR sensitized chemoresistant cancer cells by inhibiting the expression of EZH2 and PVT1 using gemcitabine-resistant pancreatic ductal adenocarcinoma cells, suggesting that CUR can overcome chemoresistance in pancreatic ductal adenocarcinoma patients via inhibition of the PRC2-PVT1-c-Myc axis. This evidence concerns the gene PVT1 and cancer.